CitationPreparation of bioactive soluble human leukemia inhibitory factor from recombinant Escherichia coli using thioredoxin as fusion partner. This is a pre-or post-print of an article published in Tomala, M., Lavrentieva, A., Moretti, P., Rinas, U., Kasper, C., Stahl, F., Schambach, A., Warlich, E., Martin, U., Cantz, T., Scheper, T. Preparation of bioactive soluble human leukemia inhibitory factor from recombinant Escherichia coli using thioredoxin as fusion partner regard to large scale cultures of these cells, LIF is needed in high quality and quantity and represents the major costs (90%) of the culture media. In this report, we describe a novel production and purification process for human LIF (hLIF) from recombinant E. coli cultures. hLIF was cloned into pET32b-trx and expressed as soluble protein in fusion with thioredoxin. After purification based on membrane adsorber technology, the fusion protein underwent cleavage by specific TEV protease. Released, soluble hLIF was subsequently purified by cation exchange chromatography and successfully tested for its biological activity using suspension cultures of murine embryonic and induced pluripotent stem cells. Our novel protocol for the production of recombinant hLIF is very suitable and effective for the production of low soluble proteins through expression in fusion with the solubilizing partner thioredoxin.